Exchange: NASDAQ·Updated 08:55 AM EDT
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026...
PR Newswire
More News
Monday 8/3 Insider Buying Report: IONS, VFC
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Friday, Ionis Pharmaceuticals' Director, Michael R. Hayden, made a $1.06M buy of...
Nasdaq News: Markets
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026...
PR Newswire
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Zacks
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +51.69% and +40.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted...
Business Wire
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results and provided key updates for the second quarter ended June 30, 2026. With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis...
Business Wire
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS PR Newswire SAN FRANCISCO, July 23, 2026 SAN FRANCISCO, July 23...
PR Newswire
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks